Management of essential thrombocythemia: Implications of the Medical Research Council Primary Thrombocythemia 1 trial

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 3, 2006, Pages 283-288

  Harrison, Claire N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Anagrelide; Essential thrombocythemia; Hydroxyurea; MRC PT 1

Indexed keywords

ACETYLSALICYLIC ACID; ANAGRELIDE; BUSULFAN; HYDROXYUREA;

ADULT; AGED; ARTERY THROMBOSIS; BLOOD SAMPLING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HIGH RISK PATIENT; HUMAN; LEUKEMOGENESIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RESEARCH; MYELOFIBROSIS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTHEMIA; VEIN THROMBOSIS;

DISEASE MANAGEMENT; HUMANS; HYDROXYUREA; QUINAZOLINES; RANDOMIZED CONTROLLED TRIALS; THROMBOCYTHEMIA, HEMORRHAGIC; TREATMENT OUTCOME;

EID: 33646485797     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-939440     Document Type: Review

References (35)

1. Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136
2. Sterkers Y, Preudhomme C, Lai JL, et al. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622
3. Murphy S. Therapeutic dilemmas: balancing the risks of bleeding, thrombosis, and leukemic transformation in myeloproliferative disorders (MPD). Thromb Haemost 1997;78: 622-626
4. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-583
5. Silverstein MN, Petitt RM, Solberg LA Jr, et al. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988; 318:1292-1294
6. Fruchtman SM, Petitt RM, Gilbert HS, Fiddler S. Anagrelide: analysis of long-term safety and leukemogenic potential in myeloproliferative disorders. Leukemia Research 2005;29: 481-491
7. Fruchtman SM, Petitt RM, Gilbert HS, et al. Anagrelide: Analysis of Long Term Safety and Leukemogenic Potential in Myeloproliferative Diseases (MPDs). Blood 2002;100:xxx (abst)
8. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45
9. Harrison CN. Platelets and thrombosis in myeloproliferative diseases. Hematology (Am Soc Hematol Educ Program) 2005;409-415
10. Jensen MK, de Nully BP, Lund BV, Nielsen OJ, Hasselbalch HC. Increased circulating platelet-leukocyte aggregates in myeloproliferative disorders is correlated to previous thrombosis, platelet activation and platelet count. Eur J Haematol 2001;66:143-151
11. Falanga A, Marchetti M, Evangelista V, et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000;96:4261-4266
12. Falanga A, Marchetti M, Vignoli A, Balducci D, Barbui T. Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera. Exp Hematol 2005;33: 523-530
13. Alvarez-Larran A, Garcia-Pagan JC, Abraldes JG, et al. Increased CD11b neutrophil expression in Budd-Chiari syndrome or portal vein thrombosis secondary to polycythaemia vera. Br J Haematol 2004;124:329-335
14. Tang SS, Frojmovic MM. Inhibition of platelet function by antithrombotic agents which selectively inhibit low-Km cyclic 3′,5′-adenosine monophosphate phosphodiesterase. J Lab CUn Med 1980;95:241-257
15. Fleming JS, Buyniski JP. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb Res 1979;15:373-388
16. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992;77:40-43
17. Bellucci S, Legrand C, Boval B, Drouet L, Caen J. Studies of platelet volume, chemistry and function in patients with essential thrombocythaemia treated with anagrelide. Br J Haematol 1999;104:886-892
18. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97:863-866
19. Petrides PE. Anagrelide: a decade of clinical experience with its use for the treatment of primary thrombocythaemia. Expert Opin Pharmacother 2004;5:1781-1798
20. Silverstein MN, Tefferi A. Treatment of essential thrombocythemia with anagrelide. Semin Hematol 1999;36:23-25
21. Thiele J, Kvasnicka HM, Fuchs N, et al. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies. Haematologica 2003;88:1130-1138
22. Lev PR, Marta RF, Vassallu P, Molinas FC. Variation of PDGF, TGFbeta, and bFGF levels in essential thrombocythemia patients treated with anagrelide. Am J Hematol 2002;70:85-91
23. Lev PR, Salim JP, Kornblihtt LI, et al. PDGF-A, PDGF-B, TGFbeta, and bFGF mRNA levels in patients with essential thrombocythemia treated with anagrelide. Am J Hematol 2005;78:155-157
24. Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study. Br J Haematol 2000;108:64-71
25. Lofvenberg E, Wahlin A, Roos G, Ost A. Reversal of myelofibrosis by hydroxyurea. Eur J Haematol 1990;44:33-38
26. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-1061
27. James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-1148
28. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-1790
29. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-397
30. Zhao R, Xing S, Li Z, et al. Identification of an acquired JAK2 mutation in Polycythemia vera. J Biol Chem 2005; 280:22788-22792
31. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 2005;366:1945-1953
32. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis. Blood 2003;101:3749 (letter)
33. Harrison CN. Essential thrombocythaemia: challenges and evidence-based management. Br J Haematol 2005;130:153-165
34. Barbui T, Barosi G, Grossi A, et al. Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-232
35. Elliott MA, Teffer A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haemost 2005;128:275-290